On January 11, 2022 Biomea Fusion, Inc. ("Biomea") (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel irreversible small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, reported it will be featured as a presenting company at the H.C. Wainwright BioConnect Conference (Press release, Biomea Fusion, JAN 11, 2022, View Sourcenews-releases/news-release-details/biomea-fusion-announces-participation-hc-wainwright-2022" target="_blank" title="View Sourcenews-releases/news-release-details/biomea-fusion-announces-participation-hc-wainwright-2022" rel="nofollow">View Source [SID1234598574]). The conference is being held on January 10-13, 2022, virtually.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Thomas Butler, Chief Executive Officer and Chairman of the Board of Biomea Fusion, will provide a corporate update during the fireside chat.

If you are an institutional investor, and would like to listen to the Company’s presentation, please click on the following link (www.hcwevents.com/bioconnect) to register for the conference. Additionally, a live audio webcast of the fireside chat can be accessed at View Source and will be available for 90 days following the presentation.